Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M333Revenue (TTM) $M46.4Net Margin (%)-197.5Altman Z-Score-9.3
Enterprise Value $M301EPS (TTM) $-0.4Operating Margin %-182.5Piotroski F-Score4
P/E(ttm)--Beneish M-Score0.5Pre-tax Margin (%)-197.8Higher ROA y-yY
Price/Book98.610-y EBITDA Growth Rate %-28.1Quick Ratio2.1Cash flow > EarningsY
Price/Sales7.25-y EBITDA Growth Rate %-24.0Current Ratio2.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-37.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-240.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M243ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with ARNA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
ARNAKen Fisher 2016-03-31 Sold Out $1.41 - $1.97
$ 1.37-15%Sold Out0
ARNAKen Fisher 2015-12-31 Add$1.7 - $2.4
$ 1.37-33%Add 0.91%11,100
ARNAKen Fisher 2013-12-31 Buy $4.08 - $6.66
$ 1.37-74%New holding11,000
ARNAMario Gabelli 2011-03-31 Sold Out $1.41 - $2.16
$ 1.37-19%Sold Out0
ARNAMario Gabelli 2010-12-31 Buy $1.27 - $2.38
$ 1.37-13%New holding13,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARNA is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

ARNA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
White Christine AnnaDirector 2016-06-13Sell18,728$1.99-31.16view
WOODS RANDALL EDirector 2015-03-30Sell76,268$4.49-69.49view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-03-17Sell70,000$5-72.6view
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-01-08Sell45,000$6.26-78.12view
SHANAHAN WILLIAM R JRSVP & Chief Medical Officer 2015-01-07Sell50,000$5.49-75.05view
LIEF JACKChairman, President and CEO 2014-07-01Sell223,525$5.85-76.58view
BELCHER DONALD DDirector 2014-06-27Sell2,473$5.85-76.58view
SPECTOR STEVEN WEVP, General Counsel & Sec 2014-05-12Sell45,000$7.05-80.57view
BELCHER DONALD DDirector 2014-05-06Sell4,176$7-80.43view
HIXSON HARRY F JRDirector 2014-04-22Sell36,900$6.31-78.29view

Quarterly/Annual Reports about ARNA:

News about ARNA:

Articles On GuruFocus.com
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
(ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
Arena Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
Arena Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
ETFs with exposure to Arena Pharmaceuticals, Inc. : December 8, 2016 Dec 08 2016
Arena Pharmaceuticals Completes Enrollment in Ralinepag Phase 2 Clinical Trial for Pulmonary... Dec 07 2016
Arena Pharmaceuticals Announces Four Upcoming Presentations at the 2016 Advances in Inflammatory... Nov 30 2016
Fabege takes on greater responsibility for Friends Arena Nov 30 2016
Should You Follow Hedge Funds Into Healthways, Inc. (HWAY)? Nov 28 2016
ETFs with exposure to Arena Pharmaceuticals, Inc. : November 28, 2016 Nov 28 2016
Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016 Nov 22 2016
ETFs with exposure to Arena Pharmaceuticals, Inc. : November 15, 2016 Nov 15 2016
Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US :... Nov 14 2016
Arena Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference Nov 09 2016
ARENA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 09 2016
Arena Pharmaceuticals Announces Poster at the American Heart Association (AHA) Scientific Sessions... Nov 09 2016
Arena (ARNA) Q3 Loss Lower than Expected, Revenues Rise Nov 08 2016
Edited Transcript of ARNA earnings conference call or presentation 7-Nov-16 9:30pm GMT Nov 07 2016
Arena Pharmaceuticals reports 3Q loss Nov 07 2016
Arena Pharmaceuticals reports 3Q loss Nov 07 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)